Related Experiment Video
Updated: Jun 28, 2026
09:31
Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography
Published on: January 27, 2023
Patent ductus arteriosus--neonatal intensive care unit registry
Helena Andrade1, Carla Loureiro, Joaquim Tiago
1Serviço de Neonatologia e Unidade de Cardiologia Pediátrica dos Hospitals da Universidade de Coimbra, Coimbra, Portugal. helenacarvalho@huc.min-saude.pt
Summary
This study investigated patent ductus arteriosus (PDA) in newborns, finding that premature infants (less than 30 weeks gestation or 1500g birth weight) require more aggressive treatment for PDA closure. Echocardiography screening is recommended for these high-risk infants.
Area of Science:
- Neonatal Intensive Care
- Pediatric Cardiology
- Perinatal Medicine
Background:
- Patent ductus arteriosus (PDA) is a common condition in premature infants.
- Effective management of PDA is crucial for improving neonatal outcomes.
- Understanding the incidence and treatment outcomes of PDA is essential for clinical practice.
Purpose of the Study:
- To evaluate the incidence, clinical course, treatment, and mortality of PDA in a Neonatal Intensive Care Unit (NICU).
- To identify risk factors and optimal management strategies for PDA in preterm neonates.
Main Methods:
- Retrospective review of medical charts of newborns admitted to the NICU from January 2001 to December 2005.
- Analysis of PDA diagnosis timing, treatment interventions (indomethacin, surgery), and associated morbidities.
Main Results:
- PDA was diagnosed in 69 newborns, with a median gestational age of 28 weeks and birth weight of 1100 grams.
- Indomethacin therapy was successful in 88% of 49 treated infants; six required subsequent surgical ligation.
- Thirty-eight newborns had associated comorbidities, and eight died.
Conclusions:
- Neonates with gestational age <30 weeks or birth weight <1500g have a higher incidence of PDA requiring treatment.
- An aggressive treatment approach, including presymptomatic prolonged indomethacin, is recommended for high-risk infants.
- Echocardiography screening for PDA is advised for all neonates <30 weeks gestation or <1500g birth weight.
